Targeting C-type lectin receptors: a high-carbohydrate diet for dendritic cells to improve cancer vaccines.
J Leukoc Biol
; 102(4): 1017-1034, 2017 10.
Article
em En
| MEDLINE
| ID: mdl-28729358
ABSTRACT
There is a growing understanding of why certain patients do or do not respond to checkpoint inhibition therapy. This opens new opportunities to reconsider and redevelop vaccine strategies to prime an anticancer immune response. Combination of such vaccines with checkpoint inhibitors will both provide the fuel and release the brake for an efficient anticancer response. Here, we discuss vaccine strategies that use C-type lectin receptor (CLR) targeting of APCs, such as dendritic cells and macrophages. APCs are a necessity for the priming of antigen-specific cytotoxic and helper T cells. Because CLRs are natural carbohydrate-recognition receptors highly expressed by multiple subsets of APCs and involved in uptake and processing of Ags for presentation, these receptors seem particularly interesting for targeting purposes.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Células Dendríticas
/
Linfócitos T Auxiliares-Indutores
/
Vacinas Anticâncer
/
Lectinas Tipo C
/
Neoplasias
Limite:
Animals
/
Humans
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article